News
Rokote Laboratories Finland Ltd is probably the only company in Europe developing a nasal COVID-19 vaccine – the administration method brings substantial benefits to combating the disease
The nasal COVID-19 vaccine can suppress the infection before the symptoms even appear. People who are not infected would not spread the disease and the pandemic could come to its end. Rokote Laboratories Finland Ltd is one of the few European companies, if not the...
Rokote Laboratories Finland Ltd received funding from Sitra to prepare decentralised clinical trial
The purpose of the funding granted by Sitra is to expedite the popularisation of decentralised and virtual research methods in Finland. Rokote Laboratories Finland Ltd will use the funding to prepare a research plan and application for a phase 1a clinical trial of a...
Rokote Laboratories Finland Ltd updates its vaccine to be more effective against new virus variants too
Rokote Laboratories Finland Ltd has decided to update its intranasal vaccine because the SARS-CoV-2 BA.4 and BA.5 virus variants have become more common. Therefore, the launch of the clinical trials will be moved to 2023. SARS-CoV-2 appears to be here to stay and able...
